Eli Lilly

Lilly's moat is built on patented drug IP, a large-scale R&D engine, regulatory expertise, clinical-trial execution, branded prescriber trust, payer access negotiations, and tightly controlled global manufacturing. Those advantages are especially visible in tirzepatide, where product demand, supply expansion, and label expansion have reinforced scale effects.

The moat is still vulnerable to the classic pharmaceutical cycle of patent expiry, reimbursement pressure, safety litigation, and competing therapies, but in the current window Lilly's combination of clinical differentiation, approved indications, and manufacturing capacity makes its position unusually strong.

Lilly's core products are highly centralized by design: they depend on patented molecules, FDA-regulated trials, prescription channels, and GMP manufacturing. That makes the business structurally resistant to the kinds of open-source, federated, or peer-to-peer disruption that matter in software or lighter hardware markets.

Meaningful disruption here is more likely to arrive through policy, generic entry after exclusivity cliffs, lower-cost manufacturing, or alternative care delivery models than through Bitcoin-native or decentralized coordination mechanisms. In the current state, decentralizability is low.